SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    L. Vanneste, P. Wolter, J.J. Oord, M. Stas, M. Garmyn, Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients., Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1
  2. 2
    N. Klossowski, A. Kislat, B. Homey, P.A. Gerber, S. Meller, Erfolgreiche Medikamentendesensibilisierung nach Vemurafenib-induziertem Arzneimittelexanthem, Der Hautarzt, 2015, 66, 4, 221

    CrossRef

  3. 3
    Simone Stadler, Kasia Weina, Christoffer Gebhardt, Jochen Utikal, New therapeutic options for advanced non-resectable malignant melanoma, Advances in Medical Sciences, 2015, 60, 1, 83

    CrossRef

  4. 4
    Clio Dessinioti, Christina Antoniou, Andreas Katsambas, Acneiform eruptions, Clinics in Dermatology, 2014, 32, 1, 24

    CrossRef

  5. 5
    Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, Christian Posch, Kim Chong, Katia Johnston, Melissa Meier, Simona Osella-Abate, Pietro Quaglino, Adil Daud, Alain Algazi, Klemens Rappersberger, Susana Ortiz-Urda, Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma, Journal of the American Academy of Dermatology, 2014, 71, 6, 1102

    CrossRef

  6. 6
    Claire Marie Reyes-Habito, Ellen K. Roh, Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer, Journal of the American Academy of Dermatology, 2014, 71, 2, 217.e1

    CrossRef

  7. 7
    Lucie Peuvrel, Brigitte Dréno, Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management, American Journal of Clinical Dermatology, 2014, 15, 5, 425

    CrossRef

  8. 8
    Saveria Pastore, Daniela Lulli, Giampiero Girolomoni, Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors, Archives of Toxicology, 2014, 88, 6, 1189

    CrossRef

  9. 9
    Jorrit J. Hornberg, Morten Laursen, Nina Brenden, Mikael Persson, Annemette V. Thougaard, Dorthe B. Toft, Tomas Mow, Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how, Drug Discovery Today, 2014, 19, 8, 1131

    CrossRef

  10. 10
    Jane Bryce, Christine B. Boers-Doets, Non-Rash Dermatologic Adverse Events Related to Targeted Therapies, Seminars in Oncology Nursing, 2014, 30, 3, 155

    CrossRef

  11. 11
    M.-C. Koeppel, N. Bonnet, P. Berbis, Reacciones adversas cutáneas a medicamentos, EMC - Dermatología, 2014, 48, 1, 1

    CrossRef

  12. You have free access to this content12
    Michael P Brown, Georgina V Long, The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation, Asia-Pacific Journal of Clinical Oncology, 2014, 10,
  13. 13
    C. Brugière, A. Stefan, C. Morice, E. Cornet, A. Moreau, S. Allouche, L. Verneuil, Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease, British Journal of Dermatology, 2014, 171, 6
  14. 14
    Mario Mandalà, Daniela Massi, Vincenzo De Giorgi, Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action, Critical Reviews in Oncology/Hematology, 2013, 88, 2, 318

    CrossRef

  15. 15
    Kenneth Y Tsai, Sasan Nowroozi, Kevin B Kim, Drug safety evaluation of vemurafenib in the treatment of melanoma, Expert Opinion on Drug Safety, 2013, 12, 5, 767

    CrossRef

  16. 16
    Alyssa Fischer, Alyx C. Rosen, Courtney J. Ensslin, Shenhong Wu, Mario E. Lacouture, Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4, Dermatologic Therapy, 2013, 26, 2
  17. 17
    Lisa Pappas-Taffer, Misha Rosenbach, Emily Y. Chu, The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma, Current Dermatology Reports, 2013, 2, 2, 84

    CrossRef

  18. 18
    Gillian M. Keating, Katherine A. Lyseng-Williamson, Vemurafenib, American Journal of Clinical Dermatology, 2013, 14, 1, 65

    CrossRef

  19. 19
    Emily Y. Chu, Karolyn A. Wanat, Christopher J. Miller, Ravi K. Amaravadi, Leslie A. Fecher, Marcia S. Brose, Suzanne McGettigan, Lydia R. Giles, Lynn M. Schuchter, John T. Seykora, Misha Rosenbach, Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study, Journal of the American Academy of Dermatology, 2012, 67, 6, 1265

    CrossRef